Current serum prolactin thresholds for distinguishing between micro- and macroadenomas are inadequate due to imprecision, insufficient consideration of individual variations, and overlooking factors like age, gender, and medical conditions, which can affect prolactin levels, making them unsuitable for generalization across all adenoma volumes and thus requiring urgent refinement to improve their accuracy and clinical applicability. This evidence concerns the gene PRL and adenoma.